An independent peptide reference — no sellers, every claim sourced

Pentadeca Arginate

Also known as PDA, pentadecapeptide arginate, BPC-157 arginate, arginate salt of BPC-157

BPC-157 supplied as an arginine salt; the peptide is identical and no study has ever tested the salt.

preclinical Recovery & tissue research chemical

At a glance

Category
Recovery & tissue
Status
research chemical
Route
subcutaneous, occasionally oral
Half-life
No pharmacokinetic study exists for this salt in any species. Claims of extended stability or duration are marketing statements, not measurements.
Molecular weight
1419.5 g/mol for the peptide itself. The mass of the arginate salt depends on the peptide-to-arginine stoichiometry, which suppliers do not state consistently; quoted figures cannot be reconciled with any published specification.
Sequence
GEPPPGKPADDAGLV - identical to BPC-157

Not approved for human use anywhere. Marketed heavily by compounding pharmacies and telehealth clinics since roughly 2024 as a distinct, more stable successor to BPC-157. It is the same pentadecapeptide with a different counterion. The FDA's own evaluation of BPC-157-related bulk drug substances covers only the free base and the acetate; it concludes that BPC-157 (free base) is "not well-characterized from the physical and chemical characterization perspective", citing inconsistent naming that does not follow USAN, INN or IUPAC standards 3. No arginate form has been nominated or evaluated.

Doping status: Prohibited (WADA S0, non-approved substances, where BPC-157 is named explicitly)

Checked against the WADA 2026 Prohibited List. For a specific product and country, Global DRO is the lookup athletes are expected to use — the List names substances, not brand names.

This is a short entry. There is little or no published research on this compound, so there is correspondingly little to report. Empty dosing or reconstitution sections mean no credible figures exist — not that they were left out.

Mechanism of action

A salt does not change the molecule that acts on tissue. In solution the arginate dissociates and what remains is the pentadecapeptide GEPPPGKPADDAGLV, the same sequence as BPC-157, plus free arginine. Any pharmacological mechanism claimed for pentadeca arginate is therefore the mechanism of BPC-157: the proposed nitric oxide pathway modulation, VEGFR2 activation and upregulation of growth factor receptors described in rodent injury models. See the BPC-157 entry for that discussion, and for how thin the human evidence there is.

The specific commercial claim is that the arginine counterion confers markedly greater stability, most often stated as roughly a thousandfold improvement at pH 3.0, the acidity of gastric fluid. That figure appears on compounding pharmacy and clinic marketing material. It does not appear in any peer-reviewed publication, no supporting stability data have been released, and no method or laboratory has been identified. It should be read as an unverified vendor claim. Arginine salts are a routine formulation choice for improving solubility and handling of acidic peptides, which is a real but pedestrian benefit and not a pharmacological upgrade.

What the research shows

There is no published research on this compound. A PubMed search for 'pentadeca arginate', 'pentadecapeptide arginate' and 'BPC-157 arginate' returns zero results. Every efficacy claim made for it is borrowed wholesale from the BPC-157 literature, which is itself overwhelmingly preclinical.

Research in humans

No published human study of the arginate salt exists, of any design, for any indication. The parent compound BPC-157 fares little better: a 2025 systematic review in orthopaedic sports medicine screened 544 papers and found 36 that met inclusion criteria, of which 35 were preclinical and exactly one was clinical 1 - a retrospective case series without a control group.

Animal and lab research

No animal study has been published on the arginate salt specifically. The rodent literature on BPC-157 covers tendon, ligament, muscle, gastrointestinal and nerve injury models, and is discussed in the BPC-157 entry. None of it was conducted with an arginine counterion, so it cannot be cited as evidence for a claimed difference between the two.

Caveats. The central problem is that the entire commercial proposition - that this is a better BPC-157 - rests on a comparative claim that has never been tested. There is no head-to-head stability study, no comparative pharmacokinetics, and no comparative efficacy data in any species. Absence of published harm is not evidence of safety here; it is simply absence of any published data at all.

What it is used for

  • Marketed for tendon, ligament and soft tissue injury - the parent compound's evidence there is 35 preclinical studies against one uncontrolled clinical case series 1
  • Marketed for gastrointestinal complaints and gut barrier function - the FDA reviewed the parent compound for ulcerative colitis and concluded there is "a lack of evidence to support the effectiveness of BPC-157 (free base) and BPC-157 acetate as a treatment for UC", identifying only a single small trial reported as a meeting abstract and no study using the oral, subcutaneous, nasal or transdermal route 3
  • Marketed as a drop-in replacement for BPC-157 after that compound's regulatory difficulties
  • None of these uses has been tested with this salt

Dosing

Route
subcutaneous in the protocols circulated by clinics
  • No dosing range is given here because none has been established. Clinic and vendor protocols reuse BPC-157 figures, typically in the 250-500 mcg per day region, but no study has determined a dose for either compound in humans: the only clinical report identified by a 2025 systematic review of 544 screened articles was an uncontrolled retrospective case series 1.
  • Where a milligram figure is quoted for pentadeca arginate, it is unclear whether it refers to peptide mass or salt mass. Since the stoichiometry is not disclosed, two products labelled the same dose may not deliver the same amount of peptide.
  • The schedule below is recorded because clinics and vendors circulate it, not because anything supports it. It is worth being blunt: these are marketing protocols for a 2024-vintage product with no published study of any kind, and the dose is dispensed in micrograms from vials labelled in milligrams, the usual decimal trap.

These figures describe what the literature and published protocols report. They are not advice and not a dosing instruction.

Protocols

Clinic and vendor marketing schedule, borrowed from BPC-157 (circulating)

user protocol — not validated

Source: Compounding-pharmacy, telehealth and vendor marketing material, which reuses BPC-157 figures

This is not a validated schedule. It is a pattern that circulates among users and sellers, reproduced because it is what people actually follow — not because it has been tested. No trial established these doses, this interval or this duration, and nobody is checking what is in the vial. Treat every number below as an assertion, not a finding.

Reported daily dose250-500 mcg subcutaneously per day, sometimes split into two, occasionally taken orally
Reported 'loading' phasea higher-frequency run of roughly 4 to 6 weeks is often marketed, followed by a lower 'maintenance' dose
Reported cycle lengthno consistent pattern; often marketed for open-ended use

This schedule is pure marketing and has no published basis whatsoever: a PubMed search for the arginate salt returns nothing, so every figure is copied from BPC-157, whose own best clinical evidence is a single uncontrolled retrospective case series out of 544 papers screened in a 2025 review 1. The central selling claim, that the arginine counterion makes the peptide roughly a thousandfold more stable at gastric pH and therefore a better oral or longer-acting product, appears only on vendor and clinic pages, with no supporting data, method or laboratory ever released; it should be read as an unverified vendor claim, not a reason to dose orally or less often. Because suppliers do not disclose the peptide-to-arginine stoichiometry, it is not even clear whether a labelled milligram figure is peptide or salt, so two products at the 'same dose' may deliver different amounts of peptide. Anecdotal effects mirror those attributed to BPC-157 and are self-reported and uncontrolled.

Schedules are reproduced as their source states them. Units, IU and milligrams explains why the figures are not interchangeable between products.

Safety

Side effects

  • No systematic safety data exist for this salt
  • Reported effects mirror those anecdotally attributed to BPC-157: injection site irritation, transient nausea, headache, light-headedness
  • All such reports are self-reported and uncontrolled

Do not use if

  • Active malignancy - the pro-angiogenic activity described for BPC-157 in animal models is a theoretical concern and has not been evaluated in an oncological setting
  • Pregnancy and breastfeeding: no data
  • Children and adolescents: no data
  • Competitive athletes under the WADA code: prohibited at all times as a non-approved substance under S0, where BPC-157 - the active moiety here - is named explicitly 2

Interactions

Not systematically studied. No interaction data exist for the salt or for BPC-157. The arginine component is nutritionally trivial at these doses and is not expected to be pharmacologically relevant on its own.

Sources